文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

晚期表皮生长因子受体突变非小细胞肺癌一线治疗的有效性与安全性:系统评价与网络Meta分析

Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
PubMed 文献 · BMJ · 2019-10-07

该系统评价与网络Meta分析纳入18项随机对照试验共4628例晚期EGFR突变NSCLC患者,比较12种一线治疗。结果显示奥希替尼与吉非替尼联合培美曲塞为基础化疗的无进展生存期和总生存期获益最佳;联合治疗总体毒性更高,厄洛替尼联合贝伐珠单抗的3级及以上不良事件最多。

要点

  • 奥希替尼与吉非替尼联合培美曲塞为基础化疗在无进展生存期和总生存期上获益最佳。
  • 联合治疗总体毒性更高,厄洛替尼联合贝伐珠单抗的3级及以上不良事件最多。
  • 外显子19缺失患者奥希替尼无进展生存期最佳,Leu858Arg突变患者吉非替尼联合培美曲塞为基础化疗最佳。

核心结论

  • 与其它一线治疗相比,奥希替尼和吉非替尼联合培美曲塞为基础化疗与晚期EGFR突变NSCLC患者最佳的无进展生存期和总生存期获益相关。

研究设计与样本

  • 系统评价与贝叶斯网络Meta分析,检索PubMed、Embase、Cochrane中央对照试验注册库、ClinicalTrials.gov及多个国际会议数据库,检索时间从建库至2019年5月20日。
  • 纳入已发表和未发表的随机对照试验,比较两种或以上晚期EGFR突变NSCLC一线治疗,共纳入18项试验、4628例患者、12种治疗。

主要发现

  • 奥希替尼的无进展生存期优于达可替尼(HR 0.74,95%可信区间0.55至1.00)、阿法替尼(HR 0.52,0.40至0.68)、厄洛替尼(HR 0.48,0.40至0.57)、吉非替尼(HR 0.44,0.37至0.52)、埃克替尼(HR 0.39,0.24至0.62)、培美曲塞为基础化疗(HR 0.24,0.17至0.33)、不含培美曲塞化疗(HR 0.16,0.13至0.20)、阿法替尼联合西妥昔单抗(HR 0.44,0.28至0.71)及吉非替尼联合培美曲塞(HR 0.65,0.46至0.92)。
  • 奥希替尼与吉非替尼联合培美曲塞为基础化疗在无进展生存期上一致(HR 0.95,95%可信区间0.72至1.24),在总生存期获益上也一致(HR 0.94,0.66至1.35)。
  • 联合治疗总体毒性更高,厄洛替尼联合贝伐珠单抗导致的3级及以上不良事件最多;不同EGFR酪氨酸激酶抑制剂毒性谱不同。
  • 外显子19缺失患者中奥希替尼无进展生存期最佳,Leu858Arg突变患者中吉非替尼联合培美曲塞为基础化疗无进展生存期最佳。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). DESIGN: Systematic review and network meta-analysis. DATA SOURCES: PubMed, Embase, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and several international conference databases, from inception to 20 May 2019. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Published and unpublished randomised controlled trials comparing two or more treatments in the first line setting for patients with advanced EGFR mutated NSCLC were included in a bayesian network meta-analysis. Eligible studies reported at least one of the following clinical outcome measures: progression free survival, overall survival, objective response rate, and adverse events of grade 3 or higher. RESULTS: 18 eligible trials involved 4628 patients and 12 treatments: EGFR tyrosine kinase inhibitors (TKIs; osimertinib, dacomitinib, afatinib, erlotinib, gefitinib, and icotinib), pemetrexed based chemotherapy, pemetrexed free chemotherapy, and combination treatments (afatinib plus cetuximab, erlotinib plus bevacizumab, gefitinib plus pemetrexed based chemotherapy, and gefitinib plus pemetrexed). Consistent with gefitinib plus pemetrexed based chemotherapy (hazard ratio 0.95, 95% credible interval 0.72 to 1.24), osimertinib showed the most favourable progression free survival, with significant differences versus dacomitinib (0.74, 0.55 to 1.00), afatinib (0.52, 0.40 to 0.68), erlotinib (0.48, 0.40 to 0.57), gefitinib (0.44, 0.37 to 0.52), icotinib (0.39, 0.24 to 0.62), pemetrexed based chemotherapy (0.24, 0.17 to 0.33), pemetrexed free chemotherapy (0.16, 0.13 to 0.20), afatinib plus cetuximab (0.44, 0.28 to 0.71), and gefitinib plus pemetrexed (0.65, 0.46 to 0.92). Osimertinib and gefitinib plus pemetrexed based chemotherapy were also consistent (0.94, 0.66 to 1.35) in providing the best overall survival benefit. Combination treatments caused more toxicity in general, especially erlotinib plus bevacizumab, which caused the most adverse events of grade 3 or higher. Different toxicity spectrums were revealed for individual EGFR-TKIs. Subgroup analyses by the two most common EGFR mutation types indicated that osimertinib was associated with the best progression free survival in patients with the exon 19 deletion, and gefitinib plus pemetrexed based chemotherapy was associated with the best progression free survival in patients with the Leu858Arg mutation. CONCLUSIONS: These results indicate that osimertinib and gefitinib plus pemetrexed based chemotherapy were associated with the best progression free survival and overall survival benefits for patients with advanced EGFR mutated NSCLC, compared with other first line treatments. The treatments resulting in the best progression free survival for patients with the exon 19 deletion and Leu858Arg mutations were osimertinib and gefitinib plus pemetrexed based chemotherapy, respectively. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018111954.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Liu J, Cai X, et al. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ. 2019. PMID: 31591158. doi:10.1136/bmj.l5460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。